Cytotoxicity News and Research

RSS

Preclinical data of Emergent BioSolutions' ES414 in mCRPC presented at PEGS 2013

Emergent BioSolutions Inc. today announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) molecule, ES414, at the 9th Annual Protein and Antibody Engineering Summit, currently underway in Boston, MA.

3 May 2013

Antioxidant boosts liver transplant outcomes

Infusion of N-acetylcysteine in liver donors can significantly improve the outcome of transplantation, research shows.

25 Feb 2013

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech, a member of the Roche Group, today announced positive results from Stage 1 of CLL11, a Phase III randomized study to investigate the efficacy and safety profile of the investigational medicine obinutuzumab (GA101) plus chlorambucil chemotherapy compared with chlorambucil alone in people with previously untreated chronic lymphocytic leukemia (CLL).

31 Jan 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013

Natural killer cell response detrimental to glioblastoma virotherapy

For the first time, researchers have demonstrated that the response of natural killer (NK) cells is detrimental to glioblastoma virotherapy, a novel way of treating malignant brain cancer by injecting a virus into the tumor.

5 Dec 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael

Approximately 20% of all breast cancer patients have overexpression of HER2 (human epidermal growth factor receptor 2), resulting in a more aggressive phenotype, and a poor prognosis.

28 Aug 2012

Biomimetic bioartificial livers and cell toxicity assays: an interview with Dr. Joris Braspenning, CEO Medicyte

Biomimetic bioartificial livers are liver organoids based on synthetic equivalents of the human extracellular matrix (ECM) which will be seeded with human cells.

1 Aug 2012

Safe optimal concentration of propolis against radiation-induced damage

Researchers determined the amount of propolis offering maximum protection against ionised radiations without being toxic to blood cells.

7 Jul 2012

Study represents starting point for future clinical applications using propolis

A team of researchers from the University of Valencia, the Universitat Politècnica de València, the University Hospital La Fe and the Universitat Autònoma de Barcelona conducted in vitro studies of cytotoxicity (cellular affection) to assess the optimal concentration level of propolis in which this natural substance extracted from bee resin would offer the maximum protection against ionised radiation and not be toxic for blood cells.

6 Jul 2012

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.

27 Jun 2012

KaloBios’ KB001 shows promise against Pa pneumonia

Phase 2a trial results with KB001 suggest the recombinant, human PEGylated monoclonal antibody fragment, under development by KaloBios Pharmaceuticals, Inc. and Sanofi Pasteur, offers potential as an alternative to antibiotics for preventing or reducing pneumonias in mechanically ventilated intensive care unit (ICU) patients heavily colonized with Pseudomonas aeruginosa (Pa).

26 Jun 2012

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma.

2 Jun 2012

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

22 May 2012

Probiodrug AG, collaborators explain interplay of key suspects in Alzheimer’s

Probiodrug AG (Probiodrug), a biotech company developing products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer's disease (AD), today announced its scientists and academics collaborators published seminal findings on the role of pyroglu Aβ in AD pathology in the May 2, 2012 online edition of the journal Nature (DOI: 10.1038/nature11060). The new findings add to the growing body of evidence that pyroglu Aβ plays a crucial role in the initiation of AD. In addition, the research results further elucidate the mechanism by which pyroglu Aβ triggers neuronal toxicity.

3 May 2012

Rise in PIP breast implant ruptures sparks fresh fears

According to the Australasian College of Cosmetic Surgery all brands of breast implants carry a risk of rupture. Spokesman Dr Daniel Fleming said a rupture rate of 13.6 per cent over eight years is a normal rate for major brand Mentor.

5 Apr 2012

EU's Safety Evaluation Ultimately Replacing Animal Testing initiative tests Roche's xCELLigence system

Roche's xCELLigence RTCA System is being used in the European Union's SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) initiative to run five years from 2011 to 2016.

From Roche Sequencing and Life Science 29 Mar 2012

Advances in Neuroimmune Biology explores maternal-fetal interactions

Fertility problems, recurrent miscarriages, and pregnancy complications can occur when maternal immunological tolerance of the fetus is impaired. G-rard Chaouat and colleagues from Inserm et Assistance Publique et Universit- Paris Sud Orsay, Hopital Antoine B-cl-re, Clamart Cedex, France, trace the evolution of the science of reproductive immunology to show how the current understanding of maternal-fetal tolerance/dialogue has developed, and its implications for the treatment of infertility disorders

22 Mar 2012

NK cells play an important role in rejection of porcine chondrocytes transplantation

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) have studied for the first time the response of human NK cells (Natural Killer) against porcine chondrocytes (cartilage cells).

23 Feb 2012

New mechanism of drug release using 3D superhydrophobic materials

According to a recent study, there is a new mechanism of drug release using 3D superhydrophobic materials that utilizes air as a removable barrier to control the rate at which drug is released.

30 Jan 2012